This study predicts that anti-CTLA-4 therapy may serve as an immunotherapeutic agent for managing cervical cancer and that the expression of CUX1, SLC2A1, and CA2 genes validated by clinical samples may serve as important targets for treatment modalities in cervical cancer. This evidence concerns the gene SLC2A1 and cervical cancer.